Most patients who walk into a Dubai aesthetic clinic ask for “Botox” the way they ask for a “Kleenex” instead of a tissue. The name has become shorthand for an entire category. But Botox is only one of several types of botulinum toxin now used in cosmetic medicine, and the differences between them are not just marketing. Formulation, molecule size, and diffusion pattern all affect how a treatment feels, how fast it works, and how long it lasts.

This guide breaks down every FDA-approved neuromodulator available today, walks through botulinum toxin type A vs type B, and compares Botox vs Dysport vs Xeomin head to head so you can have an informed conversation with your injector before your next appointment.

What Is Botulinum Toxin, and How Do Type A and Type B Differ?

Botulinum toxin is a protein produced by the bacterium Clostridium botulinum. In controlled, medical-grade doses, it blocks the release of acetylcholine at the neuromuscular junction. Acetylcholine is the chemical messenger that tells a muscle to contract, so blocking it temporarily relaxes the targeted muscle. That relaxation softens the dynamic wrinkles caused by repeated facial movement, such as frown lines, crow’s feet, and forehead creases.

There are seven known serotypes of botulinum toxin (A through G), but only types A and B have reached clinical and cosmetic use.

Type A products dominate aesthetic medicine. Botox, Dysport, Xeomin, Daxxify, and Jeuveau are all type A formulations, though each uses a different manufacturing process, stabilizing protein, and unit potency scale.

Type B is represented commercially by a single product, Myobloc (rimabotulinumtoxinB). It acts on a slightly different part of the neurotransmitter release complex, works faster in some settings, but has a shorter duration and a lower pain threshold at injection, since it is formulated at a lower pH.

FDA approval history:

Botox received its first cosmetic approval in 2002, after earlier approvals for eye muscle disorders in 1989.
Myobloc was approved in 2000 for cervical dystonia, making it the first type B product cleared in the United States.
Dysport and Xeomin followed with their own cosmetic approvals in the years after.
Jeuveau reached the market in 2019.
Daxxify was the newest arrival, approved in September 2022 for moderate to severe glabellar lines.

The practical takeaway: type A is the standard for facial rejuvenation, and type B fills a narrow, mostly medical role.

Unveil Your Next Chapter With Dynasty

Our dedicated team is here to answer your questions and guide you on your path to well-being. Get in touch today to schedule a consultation or explore our services.

Book an Appointment

The Type A Family: Botox, Dysport, Xeomin, Daxxify, and Jeuveau

All five products share the same active mechanism. What separates them is the surrounding formulation, and that difference shows up in onset speed, spread, and how long results last.

Botox (onabotulinumtoxinA)

Botox remains the most studied neuromodulator in the world, with decades of safety data behind it. It is formulated with accessory proteins that bind to the toxin molecule, which some researchers believe contributes to why a small subset of long-term, frequent users develop antibody resistance over time.

Onset: results typically begin around day 3 to day 7
Duration: usually 3 to 4 months
Best for: precise, smaller-area work such as crow’s feet, glabellar lines, and eyebrow shaping
FDA-approved uses: frown lines, crow’s feet, forehead lines, plus several medical indications including chronic migraine, hyperhidrosis, and overactive bladder

Dysport (abobotulinumtoxinA)

Dysport molecules are smaller and the formulation tends to diffuse further from the injection point than Botox. Injectors often favor it for broader muscle groups where even coverage matters more than pinpoint precision.

Onset: often visible within 2 to 4 days, among the fastest of the group
Duration: roughly 3 to 4 months, sometimes slightly longer
Best for: larger, flatter areas like the forehead
Unit note: Dysport units are not equivalent to Botox units. Most injectors use a conversion ratio in the range of 2.5 to 3 units of Dysport for every 1 unit of Botox

Xeomin (incobotulinumtoxinA)

Xeomin is often called the “naked” toxin because it contains no complexing or accessory proteins, only the core botulinum toxin molecule. That simpler formulation is why it does not require refrigeration before reconstitution and why some clinicians consider it for patients who have developed a reduced response to other type A products.

Onset: similar to Botox, around 5 to 7 days
Duration: 3 to 4 months
Best for: patients seeking a protein-free option, or those who suspect antibody resistance to other brands
Unit ratio: generally treated as a 1-to-1 conversion with Botox

Daxxify (daxibotulinumtoxinA-lanm)

Daxxify is the newest type A product and the first genuine advance in duration since Botox launched. Instead of human serum albumin, it uses a proprietary peptide excipient that stabilizes the toxin molecule. FDA trial data (the SAKURA studies) showed a median duration of about 6 months for glabellar lines, with some patients maintaining visible improvement for up to 9 months.

Onset: fast, often within 1 to 2 days
Duration: 6 months on average, longer for some patients
Best for: patients who want fewer appointments per year and are comfortable with a higher per-treatment cost
Current FDA approval: glabellar lines specifically, though many injectors use it off-label for other areas
Unit note: Daxxify units are also brand-specific and not interchangeable with Botox, Dysport, or Xeomin units

Jeuveau (prabotulinumtoxinA)

Jeuveau was developed specifically for aesthetic use rather than being adapted from a therapeutic product. Its molecular structure closely resembles Botox, and most injectors treat the two as comparable at similar unit doses.

Onset: around 3 to 5 days
Duration: 3 to 4 months
Best for: frown lines, often positioned as a value-conscious alternative to Botox
Unit ratio: broadly comparable to Botox, unit for unit

Type B: Where Myobloc Fits, and Why It's Rarely Used Cosmetically

Myobloc is the only commercially available type B botulinum toxin. It was approved in 2000, initially for cervical dystonia, with an added approval in 2019 for chronic sialorrhea (excessive drooling), often in patients with Parkinson’s disease or other neurological conditions.

A few practical reasons keep Myobloc out of the cosmetic injector’s regular toolkit:

Shorter duration. Clinical data for cervical dystonia shows effects lasting roughly 12 to 16 weeks, on the shorter end of the type A range and without the longevity advantage some type A products now offer.
Lower formulation pH. This tends to make injections sting more than type A products, which matters far more to a patient seeking a smoother forehead than to one managing a neurological muscle disorder.
No cosmetic FDA indication. Myobloc’s approvals are strictly medical, and it is not positioned or studied for aesthetic use the way Botox, Dysport, Xeomin, Daxxify, and Jeuveau are.

For neurology patients who have stopped responding to type A toxins, largely due to antibody development after years of frequent, high-dose treatment, type B can still be a genuine clinical option. Outside of that narrow scenario, it has little role in facial aesthetics.

Botox vs Dysport vs Xeomin: Side-by-Side Comparison

The three most commonly compared type A products in Dubai clinics are Botox, Dysport, and Xeomin. Here is how they stack up on the factors that actually influence a patient’s decision.

Factor	Botox	Dysport	Xeomin
Onset of visible results	5 to 7 days	2 to 4 days	5 to 7 days
Typical duration	3 to 4 months	3 to 4 months	3 to 4 months
Unit ratio vs Botox	1:1 (reference)	Roughly 2.5–3:1	Roughly 1:1
Diffusion profile	Moderate, precise	Wider spread	Moderate, precise
Accessory proteins	Yes	Yes	None
Typical cost per unit in Dubai*	Mid-range	Mid-range, often lower per unit due to higher unit count	Mid-range
Best-suited candidate	Small, defined areas; first-time patients	Larger muscle groups like the forehead	Patients with suspected resistance to other toxins, or a preference for a protein-free formula

*Pricing varies by clinic, treatment area, and total units required. Ask for a personalized quote during consultation.

Daxxify and Jeuveau are left out of this particular table because they serve different comparison points: Daxxify competes on longevity rather than onset or diffusion, and Jeuveau is most often compared to Botox on price rather than formulation.

How Dynasty Clinic's Specialists Choose the Right Toxin

No single product is the right answer for every patient, every area, or every budget. During consultation, Dynasty Clinic’s injecting physicians assess a combination of factors before recommending a specific toxin:

Muscle strength and area size. A strong, broad frontalis muscle across the forehead often responds well to a product with a wider diffusion profile, while smaller muscles around the eyes call for more precision.
Treatment history. Patients who have had frequent, high-dose treatment with one brand over many years, and who report a shorter effect duration than they used to see, may be candidates for a protein-free option or a brand switch.
Desired appointment frequency. Some patients prefer the predictability of a 3 to 4 month cycle. Others, particularly those who travel frequently or find it hard to schedule regular visits, may be better suited to a longer-acting option.
Budget and treatment goals. Cost per unit does not tell the whole story. A product that requires more units per session, or lasts longer between visits, can change the real cost per month of maintaining results.

Every treatment plan at Dynasty Clinic is developed by a licensed physician following a facial assessment, not a fixed package. Dosing and product selection are adjusted to each patient’s anatomy rather than applied as a template.

All FDA-approved botulinum toxin products have similar safety profiles when injected by a qualified provider. Common side effects include mild bruising, swelling, headache, and rare temporary drooping or asymmetry. Results appear within 3–7 days, last temporarily, and require repeat treatments. An experienced injector is key to safe, natural-looking results.

Frequently Asked Questions

Is Dysport stronger than Botox? Not in a way that translates to better results. Dysport simply uses a different unit system, so a Dysport treatment plan requires more units to achieve an equivalent effect. Strength per unit is not comparable across brands.

Can I switch from Botox to Xeomin if it stops working for me? Yes, and this is a common reason patients try Xeomin. Since it contains no complexing proteins, some patients who have developed a reduced response to Botox after years of treatment report a better outcome with Xeomin. A physician assessment beforehand helps confirm whether resistance, rather than simply a shorter interval between top-ups, is the actual cause.

Is Daxxify worth the higher cost? It depends on how much you value fewer appointments. Daxxify costs more per session, but its longer average duration, around 6 months versus 3 to 4 months for other type A products, can narrow the gap in cost per month. Patients who dislike frequent clinic visits tend to find it worthwhile; patients happy with a quarterly rhythm often stick with Botox or Jeuveau.

Book Your Consultation

The right botulinum toxin for you depends on your facial anatomy, treatment history, and goals, not on which brand happens to be trending. Dynasty Clinic’s physicians can walk you through which type A option fits your face and schedule, and confirm whether a brand switch makes sense if you feel your results have changed over time.

Book a consultation with Dynasty Clinic’s aesthetic team to build a botulinum toxin plan suited to you.

Type A vs. Type B Botulinum Toxin: Botox, Dysport, Xeomin, Daxxify, Jeuveau Compared